Zhihong Liu

Title: Innovations of Zhihong Liu in Therapeutic DLL4 Binding Proteins

Introduction

Zhihong Liu is a prominent inventor based in Gurnee, IL (US). He has made significant contributions to the field of biotechnology, particularly in the development of therapeutic proteins. With a total of 3 patents, his work focuses on innovative solutions for treating various diseases.

Latest Patents

Zhihong Liu's latest patents revolve around therapeutic DLL4 binding proteins. These improved DLL4 binding proteins include antibodies, CDR-grafted antibodies, human antibodies, and DLL4 binding fragments. They are designed to bind DLL4 with high affinity and neutralize DLL4 activity. The applications of these proteins are particularly relevant in treating or preventing cancers and tumors. They are especially useful for addressing tumor angiogenesis and other angiogenesis-dependent diseases, such as ocular neovascularization. Additionally, they target angiogenesis-independent diseases characterized by aberrant DLL4 expression or activity, including autoimmune disorders like multiple sclerosis.

Career Highlights

Zhihong Liu is currently associated with AbbVie Inc., a leading biopharmaceutical company. His work at AbbVie has allowed him to focus on groundbreaking research and development in therapeutic proteins. His contributions have been instrumental in advancing the understanding and treatment of various diseases.

Collaborations

Zhihong Liu has collaborated with notable colleagues, including Lorenzo Benatuil and Erwin R Boghaert. These collaborations have fostered a productive environment for innovation and have led to significant advancements in their respective fields.

Conclusion

Zhihong Liu's work in developing therapeutic DLL4 binding proteins showcases his commitment to innovation in biotechnology. His contributions are paving the way for new treatments that could significantly impact the lives of patients suffering from various diseases.